PURPOSE: Nonsteroidal anti-inflammatory drugs such as aspirin prevent cardiovascular disease and several prior studies suggest that nonsteroidal anti-inflammatory drugs also decrease prostate inflammation and prostate cancer risk. We investigated the association between nonsteroidal anti-inflammatory drug use, prostate specific antigen and prostate volume, hypothesizing that there would be lower prostate specific antigen and prostate volume with nonsteroidal anti-inflammatory drug use. MATERIALS AND METHODS: The Nashville Men's Health Study uses a multicenter, rapid recruitment protocol to collect clinical, biological, behavioral and body measurement data on 1,277 men older than 40 years who are scheduled for diagnostic prostate biopsy. Nonsteroidal anti-inflammatory drug use was ascertained by survey and clinical interview. Medical charts were reviewed to ascertain current prostate specific antigen, prostate volume and clinical diagnoses following biopsy. RESULTS: Approximately 46% of patients reported receiving nonsteroidal anti-inflammatory drugs, primarily aspirin (37%). After adjusting for age, race and other factors prostate volume was similar between aspirin users and nonusers (47.6 vs 46.0 ml, p = 0.16). In contrast, prostate specific antigen was significantly lower in aspirin users (7.3 vs 8.0 ng/ml, p = 0.01). The association between prostate specific antigen and aspirin was significant in men with latent prostate cancer (6.1 vs 7.3 ng/ml, p <0.01), marginal in patients with high grade prostatic intraepithelial neoplasia (5.0 vs 5.9 ng/ml, p = 0.09) and nonsignificant in those with a negative biopsy (5.6 vs 5.7 ng/ml, p = 0.64). The strongest prostate specific antigen-aspirin association was in men with cancer and a prostate volume of 60 ml or more (7.3 vs 12.7 ng/ml, p <0.01). CONCLUSIONS: Prostate specific antigen was significantly lower in aspirin users with latent cancer. Prostate volume was not associated with nonsteroidal anti-inflammatory drug use. Results suggest that aspirin may affect prostate cancer detection, suggesting a potential detection bias to address in future studies of nonsteroidal anti-inflammatory drugs and prostate cancer prevention.
PURPOSE: Nonsteroidal anti-inflammatory drugs such as aspirin prevent cardiovascular disease and several prior studies suggest that nonsteroidal anti-inflammatory drugs also decrease prostate inflammation and prostate cancer risk. We investigated the association between nonsteroidal anti-inflammatory drug use, prostate specific antigen and prostate volume, hypothesizing that there would be lower prostate specific antigen and prostate volume with nonsteroidal anti-inflammatory drug use. MATERIALS AND METHODS: The Nashville Men's Health Study uses a multicenter, rapid recruitment protocol to collect clinical, biological, behavioral and body measurement data on 1,277 men older than 40 years who are scheduled for diagnostic prostate biopsy. Nonsteroidal anti-inflammatory drug use was ascertained by survey and clinical interview. Medical charts were reviewed to ascertain current prostate specific antigen, prostate volume and clinical diagnoses following biopsy. RESULTS: Approximately 46% of patients reported receiving nonsteroidal anti-inflammatory drugs, primarily aspirin (37%). After adjusting for age, race and other factors prostate volume was similar between aspirin users and nonusers (47.6 vs 46.0 ml, p = 0.16). In contrast, prostate specific antigen was significantly lower in aspirin users (7.3 vs 8.0 ng/ml, p = 0.01). The association between prostate specific antigen and aspirin was significant in men with latent prostate cancer (6.1 vs 7.3 ng/ml, p <0.01), marginal in patients with high grade prostatic intraepithelial neoplasia (5.0 vs 5.9 ng/ml, p = 0.09) and nonsignificant in those with a negative biopsy (5.6 vs 5.7 ng/ml, p = 0.64). The strongest prostate specific antigen-aspirin association was in men with cancer and a prostate volume of 60 ml or more (7.3 vs 12.7 ng/ml, p <0.01). CONCLUSIONS:Prostate specific antigen was significantly lower in aspirin users with latent cancer. Prostate volume was not associated with nonsteroidal anti-inflammatory drug use. Results suggest that aspirin may affect prostate cancer detection, suggesting a potential detection bias to address in future studies of nonsteroidal anti-inflammatory drugs and prostate cancer prevention.
Authors: Eric J Jacobs; Carmen Rodriguez; Alison M Mondul; Cari J Connell; S Jane Henley; Eugenia E Calle; Michael J Thun Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: K Shahedi; S Lindström; S L Zheng; F Wiklund; J Adolfsson; J Sun; K Augustsson-Bälter; B-L Chang; H-O Adami; W Liu; H Grönberg; J Xu Journal: Int J Cancer Date: 2006-08-01 Impact factor: 7.396
Authors: Matthew R Smith; Judith Manola; Donald S Kaufman; William K Oh; Glenn J Bubley; Philip W Kantoff Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Jay H Fowke; Lisa B Signorello; Sam S Chang; Charles E Matthews; Maciej S Buchowski; Michael S Cookson; Flora M Ukoli; William J Blot Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: Raj S Pruthi; J Eric Derksen; Dominic Moore; Culley C Carson; Gayle Grigson; Cathy Watkins; Eric Wallen Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Girish S Kulkarni; Rami Al-Azab; Gina Lockwood; Ants Toi; Andrew Evans; John Trachtenberg; Michael A S Jewett; Antonio Finelli; Neil E Fleshner Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Ganesh S Palapattu; Siobhan Sutcliffe; Patrick J Bastian; Elizabeth A Platz; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Carcinogenesis Date: 2004-10-21 Impact factor: 4.944
Authors: Jay H Fowke; Sharon Phillips; Tatsuki Koyama; Susan Byerly; Raoul Concepcion; Saundra S Motley; Peter E Clark Journal: BJU Int Date: 2012-06-22 Impact factor: 5.588
Authors: Oleksandr N Kryvenko; Yun Wang; Sudha Sadasivan; Nilesh S Gupta; Craig Rogers; Kevin Bobbitt; Dhananjay A Chitale; Andrew Rundle; Deliang Tang; Benjamin A Rybicki Journal: Prostate Date: 2019-05-02 Impact factor: 4.104
Authors: Amit M Algotar; Patricia A Thompson; James Ranger-Moore; M Suzanne Stratton; Chiu-Hsieh Hsu; Frederick R Ahmann; Raymond B Nagle; Steven P Stratton Journal: Prostate Date: 2010-06-01 Impact factor: 4.104
Authors: Wei Tang; Jay H Fowke; Lauren M Hurwitz; Mark Steinwandel; William J Blot; Stefan Ambs Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-12-08 Impact factor: 4.090